Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults.
Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).
